News - ViroPharma


Current filters:


Popular Filters

Shire’s acquisition of ViroPharma will add $831m in revenue by 2018, says GlobalData

Shire’s acquisition of ViroPharma will add $831m in revenue by 2018, says GlobalData


Ireland-based drugmaker Shire’s (LSE: SHP) buy-out of US orphan drug company ViroPharma (Nasdaq: VPHM)…

CinryzeEuropeFinancialMergers & AcquisitionsPharmaceuticalShireUSAViroPharma

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma


Ireland-based drugmaker Shire saw its share rise 2.2% to £33.16 shortly after markets opened this morning,…

CinryzeFirazyrMergers & AcquisitionsPharmaceuticalRare diseasesShireViroPharma

Stagnant treatment future seen for inherited orphan blood diseases


Generally unimpressive treatment line-ups combined with weak product pipelines will lead to modest growth…

CinryzeMarkets & MarketingPharmaceuticalRare diseasesViroPharma

Initial PERFECT Initiative findings highlight problems with epilepsy treatment


Children suffering from prolonged, acute, convulsive seizures may not always receive timely rescue medication…


ViroPharma gets FDA backing for industrial scale Cinryze manufacturing


US biotech firm ViroPharma (Nasdaq: VPHM) says that the US Food and Drug Administration has approved…

BiotechnologyCinryzeNorth AmericaProductionRegulationReproductiveViroPharma

ViroPharma buys option to acquire Meritage Pharma


ViroPharma (Nasdaq: VPHM) has entered into an exclusive option to acquire fellow USA based Meritage Pharma,…

BudesonideMergers & AcquisitionsMeritage PharmaPharmaceuticalRare diseasesResearchViroPharma

ViroPharma to acquire DuoCort Pharma for up to $164 million, adding European orphan drug to pipeline


The USA’s ViroPharma (Nasdaq: VPHM) says it has signed a definitive agreement to acquire DuoCort…

DuoCort PharmaMergers & AcquisitionsPharmaceuticalPlenadrenRare diseasesViroPharma

Intellect Neurosciences grants ViroPharma a license to OX1 in $126.5 million deal


USA-based Intellect Neurosciences (OTCBB: ILNS.PK) has granted an exclusive license to US biotech firm…

BiotechnologyIntellect NeuroscienceLicensingPharmaceuticalRare diseasesViroPharma

ViroPharma's Buccolam gets EU approval for treatment of pediatric acute seizures


USA-based ViroPharma (Nasdaq: VPHM) said yesterday that the European Commission has granted a Centralized…


ViroPharma's Cinryze cleared for hereditary angioedema in Europe


The European Commission has granted US biotech firm ViroPharma (Nasdaq: VPHM) Centralized Marketing Authorization…

BiotechnologyCinryzeEuropePharmaceuticalRare diseasesRegulationViroPharma

ViroPharma in up to $83 million deal with Halozyme for rHuPH 20 with Cinryze


US companies Halozyme Therapeutics (Nasdaq: HALO) and ViroPharma (Nasdaq: VPHM) have signed a worldwide…

CinryzeHalozyme TherapeuticsLicensingPharmaceuticalRare diseasesResearchViroPharma

Company Spotlight



Back to top